A recent report of ours clarified the efficient anti-tumor effect of syn-miR-143 on colorectal cancer cells, which occurred by impairing the KRAS networks systematically [15]; and similar effects of syn-miR-143 were presently shown even in HER2-positive GC cells (Figure 2B,C). Here, ERBB2 is linked to gastric cancer.